How is nuchal translucency measured on ultrasound in a pregnant patient at 11 + 0 to 13 + 6 weeks gestation?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 13, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

How to Measure Nuchal Translucency on Ultrasound

Gestational Age and Timing

Nuchal translucency must be measured between 11+0 to 13+6 weeks of gestation (or 14+0 weeks by some protocols), as the measurement loses predictive value outside this narrow window. 1, 2, 3 The optimal crown-rump length (CRL) for successful NT measurement is 45-66 mm, corresponding to 11+0 to 12+6 weeks, with success rates of 81.8-84.4% compared to only 66.9% at 13 weeks. 4

Standardized Measurement Technique

Image Acquisition Requirements

The fetus must be positioned in a true midsagittal plane showing the entire fetal profile with the spine posteriorly. 1 Key technical requirements include:

  • Magnification: The image should be magnified so that the fetal head and upper thorax occupy at least 75% of the screen to ensure accurate caliper placement. 1

  • Fetal position: The fetal neck must be in a neutral position—neither hyperextended nor hyperflexed—as both extremes can artificially increase the NT measurement. 1

  • Amnion distinction: The amnion must be clearly distinguished from the overlying fetal skin, as confusion between these structures is a common source of measurement error. 1

Caliper Placement

Place calipers on the inner borders of the hypo-echoic space, measuring from the outer edge of the overlying skin to the inner edge of the underlying soft tissue covering the posterior cervical spine. 1, 3 The NT is defined as the hypo-echoic (fluid-filled) space between the overlying skin and underlying soft tissues of the posterior cervical spine. 1, 3

Always record the maximum measurement obtained during the examination, as NT thickness varies with fetal movement. 1 Multiple measurements should be taken, and the largest measurement is used for risk calculation. 1

Ultrasound Approach Selection

Transabdominal Ultrasound (Primary Method)

Transabdominal ultrasound successfully obtains NT measurements in approximately 95% of patients and should be the initial approach. 1 This method provides adequate visualization in most cases and allows for greater probe mobility to obtain optimal imaging planes. 1

Transvaginal Ultrasound (Alternative Method)

Switch to transvaginal ultrasound when optimal transabdominal views cannot be obtained, which occurs in about 5% of patients. 1 Specific indications include:

  • High body mass index limiting transabdominal visualization 1
  • Multiple abdominal surgeries or scarring 1
  • Transverse fetal lie in the lower uterus 1
  • Suboptimal transabdominal views where NT borders cannot be clearly identified 1

NT measurements are equivalent between transabdominal and transvaginal approaches when the same standardized principles are applied. 1 The higher resolution of transvaginal ultrasound can more clearly identify the amnion and NT borders in challenging cases. 1

Interpretation Thresholds

An increased NT is defined as a measurement ≥3 mm or above the 99th percentile for the crown-rump length at 11-14 weeks. 1, 2, 3 This threshold is uniformly increased at any CRL between 11 and 14 weeks. 1

NT thickness increases physiologically with crown-rump length, so gestational age must be considered when determining if a measurement is abnormal. 1, 3 The relationship follows a quadratic equation, with NT increasing between 9-12 weeks and then decreasing at 13-14 weeks. 5

Quality Assurance Considerations

Measurement of NT has been standardized through quality assurance programs established by the Fetal Medicine Foundation and the Nuchal Translucency Quality Review to minimize inter- and intra-observer variability. 1, 2 There remains considerable variability in NT measurements even among trained operators, highlighting the critical importance of:

  • Ongoing quality assessment and certification 1
  • Adherence to standardized measurement protocols 1, 2
  • Regular review of measurement technique 1

Common Pitfalls to Avoid

  • Confusing the amnion with fetal skin: This is the most common source of measurement error and can falsely elevate the NT measurement. 1

  • Measuring with the fetal neck hyperextended or hyperflexed: Both positions artificially increase NT thickness. 1

  • Insufficient magnification: Inadequate zoom prevents accurate caliper placement and increases measurement error. 1

  • Recording the minimum rather than maximum measurement: NT varies with fetal movement, and the maximum measurement must be used. 1

  • Measuring outside the 11-14 week window: The false-positive rate increases significantly with advancing gestational age, rising from 1.7% at 12-12.9 weeks to 15.1% at 14.0-14.9 weeks. 6

Special Considerations for Twin Pregnancies

In dichorionic twins, measure each fetus individually using standard singleton thresholds, as NT distribution does not differ significantly between singletons and twins. 1, 2, 7 Calculate fetus-specific risks independently for each twin. 1, 2

In monochorionic twins, calculate pregnancy-specific risk using the average NT thickness of both fetuses. 1, 2

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

First-Trimester Evaluation and Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Nuchal Translucency Scan Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Optimal crown-rump length for measuring the nuchal translucency.

Journal of clinical ultrasound : JCU, 2007

Guideline

Early Maternal Screening Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Related Questions

What are the indications for nuchal translucency (NT) ultrasound?
Is a nuchal translucency (NT) measurement of 0.3mm considered normal in a pregnancy?
What does a normal nuchal translucency (NT) measurement at 12 weeks indicate about fetal health?
What is a normal nuchal translucency (NT) measurement?
What are the next steps for a pregnant patient with increased nuchal (nuchal translucency) lucency?
What baseline investigations and assessments are required before switching a patient from rivaroxaban to apixaban?
In an adult with type 2 diabetes, HbA1c 7.39 % (target < 7 %), fasting plasma glucose 128 mg/dL, impaired renal function (creatinine 1.6 mg/dL, eGFR ≈45 mL/min), currently taking dapagliflozin 10 mg once daily and gliclazide 60 mg twice daily, what additional medication should be added to improve glycemic control while minimizing hypoglycemia and providing renal‑cardiovascular benefit?
What are the recommended lifestyle and pharmacologic strategies to raise high‑density lipoprotein (HDL) cholesterol to target levels (≥40 mg/dL in men, ≥50 mg/dL in women)?
In a type 2 diabetic patient with HbA1c 7.4 % (up from 7.1 %), fasting glucose 128 mg/dL, chronic kidney disease stage 3 (creatinine 1.6 mg/dL, estimated glomerular filtration rate ≈ 45 mL/min) who is already taking dapagliflozin 10 mg once daily and gliclazide 60 mg twice daily, what additional medication (excluding tirzepatide) should be added?
Should I order an abdominal ultrasound when evaluating a patient with abdominal pain and liver function tests?
What are the recommended acyclovir dosing regimens for herpes simplex virus (HSV) and varicella‑zoster virus (VZV) infections in immunocompetent adults, immunocompromised adults, pediatric patients, and patients with impaired renal function, and what alternative oral antivirals can be used?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.